Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: Results of phase 3, randomized, placebo-controlled trials (palace 1, 2, and 3)

Authors
Category Primary study
ConferenceInternal Medicine Journal
Year 2014
This article has no abstract
Epistemonikos ID: ca5b05122988862bdaaab29fafff3672f0894996
First added on: Apr 29, 2026